Antisense Therapeut
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 24 July 2023
- Reported shorts
- 256
- Shares on issue
- 836.305M
Antisense Therapeut (ANP) Short Interest
Antisense Therapeut (ASX:ANP) had 0.00% of shares reported as short positions as of 24 July 2023, representing 256 shares. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Antisense Therapeut
Antisense Therapeutics is a biotechnology company focused on developing RNA-based therapies for rare and debilitating genetic disorders. The company leverages antisense technology to create treatments that target specific genetic sequences, offering a unique approach to disease management. Positioned in the niche market of genetic disorder therapeutics, Antisense aims to address unmet medical needs with its innovative pipeline.
Company profile →Antisense Therapeut (ASX:ANP) has 0.00% of its shares on issue reported as short positions as of 24 July 2023, or about 256 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.35% in September 2013. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Company details
website
Be the first to discuss ANP
Start a research thread or post the first pulse update